Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2025 | Ask the Expert: Stephanie Graff answers your breast cancer questions at ESMO 2025

Stephanie Graff • 18 Oct 2025
ESMO 2025
Breast Cancer Abemaciclib Ribociclib
monarchE NATALEE

Stephanie Graff, MD, Brown University Health Cancer Institute, Providence, RI, joins us for an “Ask the Expert” session at ESMO 2025, answering global questions from breast cancer professionals, including updated data on the use of CDK4/6 inhibitors, management of endocrine therapy toxicities, survivorship care, as well as barriers to access to clinical trials. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Stephanie Graff

Evaluating patient experiences in a multidisciplinary breast cancer clinic
1:21
Evaluating patient experiences in a multidisciplinary breast cancer clinic
Stephanie Graff • 16 May 2024
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
1:48
NATALEE and monarchE: ribociclib and abemaciclib in HR+/HER2- breast cancer
Stephanie Graff • 16 May 2024
Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer
1:07
Sequencing first-line CDK4/6 inhibitors in metastatic breast cancer
Stephanie Graff • 16 May 2024
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
2:06
ELAINE 1: ESR1 mutations in ctDNA from ER+/HER2- mBC treated with lasofoxifene or fulvestrant
Stephanie Graff • 7 Dec 2022

Related Videos

HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
1:15
QoL following hypofractionated adjuvant breast RNRT: insights from the HYPORT study
Sanjoy Chatterjee • 17 May 2026
Adherence to weight loss intervention in breast cancer patients
1:09
Adherence to weight loss intervention in breast cancer patients
Jennifer Ligibel • 31 May 2026
The content of VJOncology is intended for healthcare professionals